ArticleScientific reports2026
Final adult height in Korean children with idiopathic growth hormone deficiency after growth hormone treatment.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study evaluated final adult height (FAH) outcomes and associated predictive factors in patients with idiopathic growth hormone deficiency (IGHD) treated with recombinant human growth hormone (GH). We retrospectively analyzed medical records of prepubertal patients who initiated GH treatment from August 2003. As of July 2024, FAH data were available for 60 patients (40 males, 20 females). The patients started GH therapy at a mean age of 8.5 years and were treated for an average of 6.5 years. Mean height improved from - 2.6 to - 1.1 standard deviation score (SDS) following treatment. GH treatment was initiated at a significantly younger age in females. Mean FAH was 168.5 ± 4.4 cm (- 1.1 ± 0.8 SDS) in males and 156.0 ± 3.3 cm (- 1.1 ± 0.7 SDS) in females. FAH SDS was comparable to target height SDS. Multiple regression analysis showed that FAH SDS was positively associated with initial height SDS (B = 0.72, 95% CI 0.270-1.182) and negatively associated with baseline insulin-like growth factor-1 (IGF-1) SDS (B = - 0.347, 95% CI - 0.501 to - 0.192) (Adjusted R
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.